Detalles de la búsqueda
1.
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Clin Cancer Res
; 26(13): 3287-3295, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32269053
2.
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.
J Med Chem
; 62(1): 247-265, 2019 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29672039
3.
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Cancer Discov
; 8(10): 1227-1236, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30093503
4.
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
Lung Cancer
; 110: 32-34, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28676215
5.
Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
J Med Chem
; 57(11): 4427-53, 2014 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24320965
6.
A new challenging and promising era of tyrosine kinase inhibitors.
ACS Med Chem Lett
; 5(4): 272-4, 2014 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900820
7.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
J Med Chem
; 57(11): 4720-44, 2014 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24819116
8.
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
J Med Chem
; 57(4): 1170-87, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24432909
9.
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
J Med Chem
; 56(17): 6651-65, 2013 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-23944843
10.
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
J Med Chem
; 55(18): 8091-109, 2012 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-22924734
11.
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
J Med Chem
; 54(18): 6342-63, 2011 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-21812414
Resultados
1 -
11
de 11
1
Próxima >
>>